Qube Research & Technologies LTD Catalyst Pharmaceuticals, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CPRX
# of Institutions
345Shares Held
102MCall Options Held
7.7KPut Options Held
15.4K-
Black Rock Inc. New York, NY18.7MShares$435 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$196 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$135 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$72.9 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$70.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.39B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...